Advanced or Metastatic NSCLC Clinical Trial
Official title:
A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10375 Monotherapy in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04526691 -
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
|
Phase 1 | |
| Active, not recruiting |
NCT05941897 -
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT04942301 -
PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy
|
Phase 1 | |
| Recruiting |
NCT04612751 -
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03673332 -
Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies
|
Phase 4 | |
| Completed |
NCT04177290 -
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
|
Phase 1 |